Corrigendum to ‘Transplant oncology – Current indications and strategies to advance the field’ [JHEP Reports 6 (2024) 100965]
Felix J. Krendl(Innsbruck Medical University), Manuel Maglione(Innsbruck Medical University), Ruben Bellotti(Universität Innsbruck), Christian Margreiter(Innsbruck Medical University), Stefan Schneeberger(Innsbruck Medical University), Herbert Tilg(Innsbruck Medical University), Stefan Scheidl(Innsbruck Medical University), Gonzalo Sapisochín(Hebron University), Benedikt Schaefer(Universität Innsbruck), Rupert Oberhuber(Universität Innsbruck)
Cited by 2
Related Papers
Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients
|Transplantation|2017|309
Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease
|Clinical Immunology|2004|157
A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis
|Gastroenterology|2003|91
Adiponectin: Key Player in the Adipose Tissue-Liver Crosstalk
|Current Medicinal Chemistry|2012|90